drugset / Trial / NCT01045083
A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
RandomizedCrossoverSingle-blindDiagnostic
Summary
This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basimglurant | Small molecule | — | Oral |
| Subject | Escitalopram | Small molecule | — | Oral |
| Subject | Methylphenidate | Small molecule | — | Oral |
Indications
No indication recorded.